Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead cMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.13 (4.81%)
Data as of 03/31/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
02/26/15Exelixis to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3Printer Friendly Version
02/24/15Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate UpdatePrinter Friendly Version
02/19/15Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced MelanomaPrinter Friendly Version
02/02/15Exelixis to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 24, 2015Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2013 Annual Report (pdf)
Download Documentation2012 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.